{"id":751996,"date":"2023-04-27T08:39:16","date_gmt":"2023-04-27T12:39:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/"},"modified":"2023-04-27T08:39:16","modified_gmt":"2023-04-27T12:39:16","slug":"intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/","title":{"rendered":"Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., April  27, 2023  (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2023 financial results and operational highlights in a conference call on May 4, 2023, at 8 a.m. ET.<\/p>\n<p>To join the call:<\/p>\n<ul type=\"disc\">\n<li>U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.<\/li>\n<li>Please visit this <a href=\"https:\/\/event.choruscall.com\/mediaframe\/webcast.html?webcastid=VPdwU6ps\" rel=\"nofollow noopener\" target=\"_blank\">link<\/a> for a simultaneous live webcast of the call.<\/li>\n<\/ul>\n<p>A replay of the call will be available through the Events and Presentations page of the Investors &amp; Media section on Intellia\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EfWtvqSFibuOV3tCy2y9grbcL8W_h0hI9QI9Ix4YiqB5fIsujaymL59aIycfBYVnL5MXMyPNYfu77SEXqULywZS8wvB2Ev7qXI8IHHV238k=\" rel=\"nofollow noopener\" target=\"_blank\">www.intelliatx.com<\/a>, beginning on May 4, 2023, at 12 p.m. ET.<\/p>\n<p>\n        <strong>About Intellia Therapeutics<\/strong>\n      <\/p>\n<p>Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company\u2019s <em>in vivo<\/em> programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia\u2019s <em>ex vivo<\/em> programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia\u2019s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jcKd4YYPmK5eCEL8W6vKMcKHH5P7x1pGtgEyZncDtC-3dt2q-LqaqXT69vsBTBr8HyNCYDJ60wvxETj55DQTWONurc2G-wsBOi5pxUrN4W2L31yKdS00UhOndlQ0t-_YtaUlNE9S0Rzh7ZdPhV6rOxMByY53G2YivEU9XP0zKGeO6NiMKrdUog0VEVzTkhE3L6GvWWcBu0xsk7cy0Er65IlJThne_tB1SxqAs5ZHWnpgIM-_BKkw-sRF_Rl4WLLENbBcSYAeTZeAHcUcVtC1apNOyzd4OEp6-iU8dbBs7zYzfqdewbUwB4Q0LXKivGNKPSp_VSdxXLpAyQ4BaiUUZu_iF_PisxSNqiTJrEpVm4XvrGALbjqa_Tsph-frPd8j5S_cmwR27fgRVHkdcTmKLWGx7x7rBPNWk_PIuxERaXY=\" rel=\"nofollow noopener\" target=\"_blank\">intelliatx.com<\/a>. Follow us on Twitter\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZYizvjbslVcI9GQuDTawI88AqDnnZCNa1siUbRXJkBejTl337jgMcPg-DWAYgy6TcIA3mrZtcaINzYw6j-OS0QB6RPYgl69OU00qjuP5T486M1MpNcihG6pHZ9vvIUaMTdjgFch98Of1cYMsCRKXTCWGkYj8DQvPBPZFYpNrp_l8ARlrdxiW65HVyxAL1fqmTud8ZNKz4atfdbNq-fHCsRwaOjpxHl7Dlb3PnJSUbd0=\" rel=\"nofollow noopener\" target=\"_blank\">@intelliatx<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <em>Intellia Contacts:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Ian Karp<br \/>Senior Vice President, Investor Relations and Corporate Communications<br \/>+1-857-449-4175<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vl42VVGkOzY7vrmoD60r6_QQhu6Js69MMNDYY5HFzsV3L4jvQyt06v8aMPImv_idV7w36BQVM4yGK8DbOVqyEUEU5oGo8zQf_YRL_VsWG5s=\" rel=\"nofollow noopener\" target=\"_blank\">ian.karp@intelliatx.com<\/a><\/p>\n<p>Lina Li<br \/>Senior Director, Investor Relations and Corporate Communications<br \/>+1-857-706-1612<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pN9XbLuCcq_wFmQo6kYHGGHVoCRtO1ndLksbUj4IzowQeO549vzbpl01mn7BUWrTwj9vpKGMbsh8bqzxdYJ2eGIqzP2I0Y4VNTSEOi30l74=\" rel=\"nofollow noopener\" target=\"_blank\">lina.li@intelliatx.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEwMiM1NTU4Nzk4IzIwMjkyMDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzVkOWQ3N2QtMGM1MS00NGY5LWE0NjktYTE5MWVkYmZmNzQ5LTEwNDA3NzI=\/tiny\/Intellia-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2023 financial results and operational highlights in a conference call on May 4, 2023, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call. Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available through the Events and Presentations page of the Investors &amp; Media section on Intellia\u2019s website at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751996","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2023 financial results and operational highlights in a conference call on May 4, 2023, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call. Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available through the Events and Presentations page of the Investors &amp; Media section on Intellia\u2019s website at &hellip; Continue reading &quot;Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-27T12:39:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEwMiM1NTU4Nzk4IzIwMjkyMDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates\",\"datePublished\":\"2023-04-27T12:39:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\\\/\"},\"wordCount\":317,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjEwMiM1NTU4Nzk4IzIwMjkyMDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\\\/\",\"name\":\"Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjEwMiM1NTU4Nzk4IzIwMjkyMDE=\",\"datePublished\":\"2023-04-27T12:39:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjEwMiM1NTU4Nzk4IzIwMjkyMDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjEwMiM1NTU4Nzk4IzIwMjkyMDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/","og_locale":"en_US","og_type":"article","og_title":"Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates - Market Newsdesk","og_description":"CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2023 financial results and operational highlights in a conference call on May 4, 2023, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call. Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available through the Events and Presentations page of the Investors &amp; Media section on Intellia\u2019s website at &hellip; Continue reading \"Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-27T12:39:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEwMiM1NTU4Nzk4IzIwMjkyMDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates","datePublished":"2023-04-27T12:39:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/"},"wordCount":317,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEwMiM1NTU4Nzk4IzIwMjkyMDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/","name":"Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEwMiM1NTU4Nzk4IzIwMjkyMDE=","datePublished":"2023-04-27T12:39:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEwMiM1NTU4Nzk4IzIwMjkyMDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEwMiM1NTU4Nzk4IzIwMjkyMDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-company-updates\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751996"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751996\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}